Tacrolimus modulates dendritic cell activation in the sensitization phase of allergic contact dermatitis

Skin Pharmacology and Physiology

Volumn 23, Issue 1, 2010, Pages 53-59

  Ott, Hagen ^a   Baron, J M ^a   Heise, R ^a   Skazik, C ^a   Merk, H F ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cinnamic aldehyde; Contact hypersensitivity; Dendritic cells; Tacrolimus

Indexed keywords

BETAMETHASONE; CINNAMALDEHYDE; INTERLEUKIN 8; TACROLIMUS; TRINITROBENZENESULFONIC ACID;

ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIZATION; SKIN ALLERGY; UPREGULATION;

ACROLEIN; ANTIGEN-PRESENTING CELLS; BETAMETHASONE; CELL LINE, TUMOR; DENDRITIC CELLS; DERMATITIS, ALLERGIC CONTACT; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-8; MONOCYTES; POLYMERASE CHAIN REACTION; TACROLIMUS; TRINITROBENZENESULFONIC ACID;

EID: 76749151347     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000257264     Document Type: Article

References (49)

1. Diepgen TL, Weisshaar E: Contact dermatitis: epidemiology and frequent sensitizers to cosmetics. J Eur Acad Dermatol Venereol 2007; 21(suppl 2):9-13.
2. Fujii Y, Takeuchi H, Sakuma S, Sengoku T, Takakura S: Characterization of a 2,4-dinitrochlorobenzene-induced chronic dermatitis model in rats. Skin Pharmacol Physiol 2009; 22: 240-247.
3. Gibbs S: In vitro irritation models and immune reactions. Skin Pharmacol Physiol 2009; 22: 103-113.
4. Merk HF, Sachs B, Baron J: The skin: target organ in immunotoxicology of small-molecular-weight compounds. Skin Pharmacol Appl Skin Physiol 2001; 14: 419-430.
5. Traidl C, Merk HF, Cavani A, Hunzelmann N: New insights into the pathomechanisms of contact dermatitis by the use of transgenic mouse models. Skin Pharmacol Appl Skin Physiol 2000; 13: 300-312.
6. Basketter D, Darlenski R, Fluhr JW: Skin irritation and sensitization: mechanisms and new approaches for risk assessment. Skin Pharmacol Physiol 2008; 21: 191-202.
7. Karlberg AT, Bergstrom MA, Borje A, Luthman K, Nilsson JL: Allergic contact dermatitis-Formation, structural requirements, and reactivity of skin sensitizers. Chem Res Toxicol 2008; 21: 53-69.
8. Merk HF, Baron JM, Neis MM, Obrigkeit DH, Karlberg AT: Skin: major target organ of allergic reactions to small molecular weight compounds. Toxicol Appl Pharmacol 2007; 224: 313-317.
9. Fluhr JW, Darlenski R, Angelova-Fischer I, Tsankov N, Basketter D: Skin irritation and sensitization: mechanisms and new approaches for risk assessment. 1. Skin irritation. Skin Pharmacol Physiol 2008; 21: 124-135. (Pubitemid 351793741)
10. Novak N, Kwiek B, Bieber T: The mode of topical immunomodulators in the immunological network of atopic dermatitis. Clin Exp Dermatol 2005; 30: 160-164.
11. Kalthoff FS, Winiski A, Fichtinger P, Schwendinger B, Wang S, Weishaeupl C, Stuetz A: Differential inhibition of primary versus preactivated T cells by pimecrolimus but not by tacrolimus in vitro. Int Arch Allergy Immunol 2007; 142: 255-264.
12. Homey B, Assmann T, Vohr HW, Ulrich P, Lauerma AI, Ruzicka T, Lehmann P, Schuppe HC: Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol 1998; 160: 5331-5340.
13. Pacor ML, Di Lorenzo G, Martinelli N, Mansueto P, Friso S, Pellitteri ME, Di Fede G, Rini G, Corrocher R: Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis. Allergy Asthma Proc 2006; 27: 527-531.
14. Alomar A, Puig L, Gallardo CM, Valenzuela N: Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Dermatitis 2003; 49: 185-188.
15. Kato A, Chustz RT, Ogasawara T, Kulka M, Saito H, Schleimer RP, Matsumoto K: Dexamethasone and FK506 inhibit expression of distinct subsets of chemokines in human mast cells. J Immunol 2009; 182: 7233-7243.
16. Sengoku T, Kishi S, Sakuma S, Ohkubo Y, Goto T: FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol 2000; 22: 189-201.
17. Park CW, Lee BH, Han HJ, Lee CH, Ahn HK: Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol 2005; 152: 1173-1181.
18. Bäumer W, Sülzle B, Weigt H, De Vries VC, Hecht M, Tschernig T, Kietzmann M: Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis. Br J Dermatol 2005; 153: 136-144.
19. Matsue H, Yang C, Matsue K, Edelbaum D, Mummert M, Takashima A: Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol 2002; 169: 3555-3564.
20. Cos J, Villalba T, Parra R, Gallardo D, Bilbao I, Margarit C, Massuet L: FK506 in the maturation of dendritic cells. Haematologica 2002; 87: 679-687.
21. Baumer W, Krekeler S, De Vries VC, Niedorf F, Tschernig T, Kietzmann M: Non-steroidal and steroidal anti-inflammatory drugs vary in their modulation of dendritic cell function in the elicitation phase of allergic contact dermatitis. Exp Dermatol 2006; 15: 322-329.
22. Koopman G, Dalgleish AG, Bhogal BS, Haaksma AG, Heeney JL: Changes in dendritic cell subsets in the lymph nodes of rhesus macaques after application of glucocorticoids. Hum Immunol 2001; 62: 208-214.
23. Ott H, Bergstrom MA, Heise R, Skazik C, Zwadlo-Klarwasser G, Merk HF, Baron JM, Karlberg AT: Cutaneous metabolic activation of carvoxime, a self-activating, skinsensitizing prohapten. Chem Res Toxicol 2009; 22: 399-405.
24. Cluzel-Tailhardat M, Bonnet-Duquennoy M, de Queral DP, Vocanson M, Kurfurst R, Courtellemont P, Le Varlet B, Nicolas JF: Chemicals with weak skin sensitizing properties can be identified using low-density microarrays on immature dendritic cells. Toxicol Lett 2007; 174: 98-109.
25. Pichowski JS, Cumberbatch M, Dearman RJ, Basketter DA, Kimber I: Allergen-induced changes in interleukin 1 beta (IL-1 beta) mRNA expression by human blood-derived dendritic cells: inter-individual differences and relevance for sensitization testing. J Appl Toxicol 2001; 21: 115-121.
26. van Kooten C, Stax AS, Woltman AM, Gelderman KA: Handbook of experimental pharmacology 'dendritic cells': the use of dexamethasone in the induction of tolerogenic DCs. Handb Exp Pharmacol 2009; 188: 233-249.
27. Toebak MJ, de Rooij J, Moed H, Stoof TJ, von Blomberg BM, Bruynzeel DP, Scheper RJ, Gibbs S, Rustemeyer T: Differential suppression of dendritic cell cytokine production by anti-inflammatory drugs. Br J Dermatol 2008; 158: 225-233.
28. Hackstein H, Thomson AW: Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4: 24-34.
29. Bickers D, Calow P, Greim H, Hanifin JM, Rogers AE, Saurat JH, Sipes IG, Smith RL, Tagami H: A toxicologic and dermatologic assessment of cinnamyl alcohol, cinnamaldehyde and cinnamic acid when used as fragrance ingredients. Food Chem Toxicol 2005; 43: 799-836.
30. Cheung C, Hotchkiss SA, Pease CK: Cinnamic compound metabolism in human skin and the role metabolism may play in determining relative sensitisation potency. J Dermatol Sci 2003; 31: 9-19.
31. Dearman RJ, Wright ZM, Basketter DA, Ryan CA, Gerberick GF, Kimber I: The suitability of hexyl cinnamic aldehyde as a calibrant for the murine local lymph node assay. Contact Dermatitis 2001; 44: 357-361.
32. Girardin P, Vigan M, Humbert P, Aubin F: Cross-reactions in patch testing with ketoprofen, fragrance mix and cinnamic derivatives. Contact Dermatitis 2006; 55: 126-128.
33. Smith CK, Moore CA, Elahi EN, Smart AT, Hotchkiss SA: Human skin absorption and metabolism of the contact allergens, cinnamic aldehyde, and cinnamic alcohol. Toxicol Appl Pharmacol 2000; 168: 189-199.
34. Aeby P, Wyss C, Beck H, Griem P, Scheffler H, Goebel C: Characterization of the sensitizing potential of chemicals by in vitro analysis of dendritic cell activation and skin penetration. J Invest Dermatol 2004; 122: 1154-1164.
35. Ryan CA, Kimber I, Basketter DA, Pallardy M, Gildea LA, Gerberick GF: Dendritic cells and skin sensitization: biological roles and uses in hazard identification. Toxicol Appl Pharmacol 2007; 221: 384-394.
36. dos Santos GG, Reinders J, Ouwehand K, Rustemeyer T, Scheper RJ, Gibbs S: Progress on the development of human in vitro dendritic cell based assays for assessment of the sensitizing potential of a compound. Toxicol Appl Pharmacol 2009; 236: 372-382.
37. Nukada Y, Miyazawa M, Kosaka N, Ito Y, Sakaguchi H, Nishiyama N: Production of IL-8 in THP-1 cells following contact allergen stimulation via mitogen-activated protein kinase activation or tumor necrosis factor-alpha production. J Toxicol Sci 2008; 33: 175-185.
38. Toebak MJ, Pohlmann PR, Sampat-Sardjoepersad SC, von Blomberg BM, Bruynzeel DP, Scheper RJ, Rustemeyer T, Gibbs S: CXCL8 secretion by dendritic cells predicts contact allergens from irritants. Toxicol In Vitro 2006; 20: 117-124.
39. Woltman AM, de Fijter JW, Kamerling SW, Paul LC, Daha MR, van Kooten C: The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol 2000; 30: 1807-1812.
40. Piemonti L, Monti P, Allavena P, Sironi M, Soldini L, Leone BE, Socci C, Di Carlo V: Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999; 162: 6473-6481.
41. Sehgal VN, Srivastava G, Dogra S: Tacrolimus in dermatology- pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects. Part 1. Skinmed 2008; 7: 27-30.
42. Ehrchen J, Sunderkotter C, Luger T, Steinhoff M: Calcineurin inhibitors for the treatment of atopic dermatitis. Expert Opin Pharmacother 2008; 9: 3009-3023.
43. Shimizu K, Fujii S, Fujimoto K, Kawa K, Yamada A, Kawano F: Tacrolimus (FK506) treatment of CD34+ hematopoietic progenitor cells promote the development of dendritic cells that drive CD4+ T cells toward Th2 responses. J Leukoc Biol 2000; 68: 633-640.
44. Panhans-Gross A, Novak N, Kraft S, Bieber T: Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107: 345-352.
45. Lee YH, Lee YR, Im SA, Park SI, Kim KH, Gerelchuluun T, Song S, Kim K, Lee CK: Calcineurin inhibitors block MHC-restricted antigen presentation in vivo. J Immunol 2007; 179: 5711-5716.
46. Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A, Thomson AW: Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457-4463.
47. Bottcher I, Bellinghausen I, Konig B, Knop J, Saloga J: Different regulation of T helper 1-and T helper 2-promoting cytokine signalling factors in human dendritic cells after exposure to protein versus contact allergens. Immunology 2008; 123: 139-144.
48. Bavandi A, Fahrngruber H, Aschauer H, Hartmann B, Meingassner JG, Kalthoff FS: Pimecrolimus and tacrolimus differ in their inhibition of lymphocyte activation during the sensitization phase of contact hypersensitivity. J Dermatol Sci 2006; 43: 117-126.
49. Novak N, Baurecht H, Schafer T, Rodriguez E, Wagenpfeil S, Klopp N, Heinrich J, Behrendt H, Ring J, Wichmann E, Illig T, Weidinger S: Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol 2008; 128: 1430-1435. (Pubitemid 351693185)